help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/ajpath.2007.061205 on April 19, 2007

Published online before print April 19, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajpath.2007.061205v1
170/6/2122    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shen, X. Z.
Right arrow Articles by Bernstein, K. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shen, X. Z.
Right arrow Articles by Bernstein, K. E.
(American Journal of Pathology. 2007;170:2122-2134.)
© 2007 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2007.061205

Mice with Enhanced Macrophage Angiotensin-Converting Enzyme Are Resistant to Melanoma

Xiao Z. Shen*, Ping Li*, Daiana Weiss{dagger}, Sebastien Fuchs*, Hong D. Xiao*, Jon A. Adams*, Ifor R. Williams*, Mario R. Capecchi{ddagger}, W. Robert Taylor{dagger} and Kenneth E. Bernstein*

From the Department of Pathology and Laboratory Medicine,* Emory University, Atlanta, Georgia; the Department of Medicine,{dagger} Emory University, Atlanta, Georgia; and the Howard Hughes Medical Institute,{ddagger} Eccles Institute of Human Genetics, University of Utah, Salt Lake City, Utah

Angiotensin-converting enzyme (ACE) is a peptidase responsible for the cleavage of angiotensin I and several other peptides. Here, gene targeting was used to switch control of the ACE locus from the endogenous promoter to the macrophage-specific c-fms promoter. Challenge of these mice, called ACE 10/10, with the aggressive mouse melanoma cell line B16 showed that they are remarkably resistant to tumor growth. Tumor resistance was seen after challenge with different melanoma cell lines and in mice with different genetic backgrounds. Histological study of the tumors that did grow in ACE 10/10 mice showed an enhanced inflammatory response. ACE 10/10 mice had increased numbers of tumor epitope-specific CD8+ T cells after challenge with melanoma or lymphoma. ACE 10/10 macrophages showed increased production of interleukin-12 and nitric oxide but reduced interleukin-10. Engraftment of wild-type mice with ACE 10/10 bone marrow transferred B16 tumor resistance. Injection of B16 tumors with ACE 10/10 macrophages also reduced tumor growth. ACE 10/10 mice may define a new means of enhancing the immune response, which may be potentially useful in several human clinical situations.




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
E. I. Ager, J. Neo, and C. Christophi
The renin-angiotensin system and malignancy
Carcinogenesis, September 1, 2008; 29(9): 1675 - 1684.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Z. Shen, A. E. Lukacher, S. Billet, I. R. Williams, and K. E. Bernstein
Expression of Angiotensin-converting Enzyme Changes Major Histocompatibility Complex Class I Peptide Presentation by Modifying C Termini of Peptide Precursors
J. Biol. Chem., April 11, 2008; 283(15): 9957 - 9965.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
L. Rush

Vet. Pathol., November 1, 2007; 44(6): 965 - 965.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society for Investigative Pathology.